Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD1 | O95696 | 1/20 | 0.35 |
| ▸ | TAF1 | P21675 | 1/20 | 0.35 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.35 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.33 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | PRNP | P04156 | 1/20 | 0.31 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.30 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | BTK | Q06187 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18000197 | 0.78 | CMA1 (0.37) | BRD1TAF1BRPF1HRH4HSD11B1 | |
| SCHEMBL27699961 | 0.74 | BRD1 (0.33) | BRD1TAF1BRPF1JAK2BTK | |
| SCHEMBL20604986 | 0.74 | AR (0.44) | BRD1TAF1BRPF1 | |
| SCHEMBL3568292 | 0.73 | MEN1 (0.34) | BRD1TAF1BRPF1HRH4 | |
| SCHEMBL3554228 | 0.73 | TRIM24 (0.36) | BRD1TAF1BRPF1HRH4MDM2 | |
| SCHEMBL689437 | 0.72 | MCL1 (0.56) | — | |
| SCHEMBL3559963 | 0.70 | MCL1 (0.39) | BRD1TAF1BRPF1HRH4MDM2 | |
| Hydrochloric Acid SCHEMBL3559968 | 0.70 | MCL1 (0.54) | — | |
| SCHEMBL3566855 | 0.69 | MCL1 (0.38) | BRD1TAF1BRPF1HRH4 | |
| SCHEMBL21432468 | 0.69 | GPR3 (0.45) | GRM2JAK2BTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107108512-B | Therapeutic compounds and uses thereof | 基因泰克公司 | 2021-05-04 | — | — | CN | disclosed |
| EP-3204360-B1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH INC (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10206931-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-10206931-B2 | Therapeutic compounds and uses thereof | GENENTECH, INC. (US) | 2019-02-19 | — | — | US | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | WUXI APPTEC (SHANGHAI) CO. LTD (CN) | 2017-11-02 | — | — | US | disclosed |
| EP-3204360-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | Genentech, Inc. (US) | 2017-08-16 | — | — | EP | disclosed |
| WO-2016055028-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | GENENTECH, INC. (US) | 2016-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170312292-A1 | THERAPEUTIC COMPOUNDS AND USES THEREOF | EP300, CREBBP, HDAC1 | BRD1 43/4885TAF1 207/4885BRPF1 236/4885 |
| US-10206931-B2 | Therapeutic compounds and uses thereof | EP300, CREBBP, HDAC1 | BRD1 43/4885TAF1 207/4885BRPF1 236/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.